Phase 1/2a first patient to be enrolled H2 2017Process development in progressPhase 1/2a in progress; positive data presented 9/2016 and 1/2017Process development & enhancement in progressPh 1/2a First patient to enroll H2 2017Ph 1/2a ongoingAST-VAC2**

Lung Cancer Allogeneic

Potential in multiple cancer types/stages as well as combination therapyAST-VAC1**

Leukemia (AML) Autologous
Potential in multiple cancer types/stages as well as combination therapyAST-OPC1*

Spinal Cord Injury (subacute)
Potential for application in advanced MS, stroke

STATUS

  • PHASE 3
  • PHASE 2
  • PHASE 1
  • PRECLIN
  • PROGRAM

Asterias is not providing any investigational medicinal product for expanded access (use of the investigational medicinal product outside the context of a clinical trial and commonly referred to as compassionate use).